Goldman Sachs
CRVS icon

Goldman Sachs’s Corvus Pharmaceuticals CRVS Stock Holding History

Goldman Sachs’s Portfolio CRVS Stock Details CRVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-500,000
Closed -$1.59M – 6122
2025
Q1 		$1.59M Hold
500,000
– – ﹤0.01% 4341
2024
Q4 		$2.67M Hold
500,000
– – ﹤0.01% 4039
2024
Q3 		$2.64M Buy
+500,000
New +$1.8M ﹤0.01% 3905

Other funds holding CRVS

OrbiMed
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
ASP
Adams Street Partners Chicago, Illinois $443M AUM 49.46% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Perceptive Advisors
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Deep Track Capital
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Goldman Sachs's CRVS Position: Q2 2026 in Review

Goldman Sachs increased its Corvus Pharmaceuticals (CRVS) stake by 2.3% in Q2 2026, buying an estimated $493K and bringing the position to 1,576,352 shares worth $23.6M. The position accounts for ﹤0.01% of the portfolio, ranked #2468.

Goldman Sachs first reported a position in CRVS in Q1 2016 and has held it in 34 quarters since. 173 funds tracked by Wall St. Rank hold CRVS as of Q2 2026.

  • Goldman Sachs held 1,576,352 shares of Corvus Pharmaceuticals worth $23.6M as of Q2 2026.
  • Goldman Sachs bought 35,543 Corvus Pharmaceuticals shares in Q2 2026, an estimated $493K.
  • Corvus Pharmaceuticals made up ﹤0.01% of Goldman Sachs's portfolio in Q2 2026, its #2468 holding.
  • Goldman Sachs first reported a position in Corvus Pharmaceuticals in Q1 2016 and has held it in 34 quarters since.
  • 173 funds tracked by Wall St. Rank held Corvus Pharmaceuticals as of Q2 2026.

Based on Goldman Sachs's 13F filing for Q2 2026, filed 14 Aug 2026.